Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QT-Evaluation Study of APL-130277 in Parkinson's Disease
NCT03187301Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Aug 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of apomorphine in Parkinson's disease (PD), sponsored by Sumitomo Pharma America. Started Aug 2017; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03187301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187301.